✦ LIBER ✦

397: Everolimus with reduced cyclosporine exposure vs. MMF and conventional cyclosporine: Results from a study in de novo heart transplant recipients

✍ Scribed by H. Lehmkuhl; U. Livi; P. Boissonnat; J. Arizon; M. Vigano; C. Magelli; L. Almenar; K.H. Abeywickrama; Y. Gezahegen

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

15: Results of a 12-Month, Multicenter,

✍ H. Lehmkuhl; U. Livi; J. Arizon; M. Viganò; C. Magelli; P. Boissonnat; G. Gerosa 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 112 KB

12-month safety and efficacy of everolim

✍ Helio Tedesco-Silva Jr; Stefan Vitko; Julio Pascual; Josette Eris; John C. Magee 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 504 KB

One-Year Results with Extended-Release T

✍ H. T. Silva Jr; H. C. Yang; M. Abouljoud; P. C. Kuo; K. Wisemandle; P. Bhattacha 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB

55 Everolimus with Reduced CsA vs MMF wi

✍ H. Eisen; D. Pauly; R. Starling; H. Lehmkuhl; H. Ross; A. Kfoury; S. Wang; B. Ca 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 289 KB

Efficacy and safety of de novo or early

✍ Jacques Dantal; François Berthoux; Marie-Christine Moal; Lionel Rostaing; Christ 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 335 KB

The safety and efficacy of sirolimus and

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 191 KB